CGT IND/BLA Strategy: Paths to Gene Therapy Approval
Capabilities
A well-designed CGT IND BLA strategy is critical for gene therapy developers looking to accelerate timelines without sacrificing scientific or regulatory integrity. From early feasibility studies through process validation and commercial readiness, this video explores how a platform-based, regulatory-informed strategy can streamline every CMC milestone from IND to BLA/MAA submission.
Register to watch the video and learn how integrated development thinking helps reduce risk, lower cost, and align quality with long-term success.
Why the Right CGT IND BLA Strategy Matters
Cell and gene therapy products face unique development hurdles. Unlike traditional biologics, the complexity of viral vectors, potency testing, serotype-specific assays and platform scalability requires precise planning—right from the candidate selection phase. The video breaks down why a purpose-built CMC roadmap is the foundation of a successful regulatory journey.
You’ll explore:
- What to consider when choosing between modular vs. integrated development
- How early data generation supports long-term regulatory goals
- Why “beginning with the end in mind” is more than just a cliché in CGT
Strategic Drivers from IND to BLA
Pharmaron’s approach highlights three central pillars of success for a gene therapy CMC strategy:
1.End-to-End Planning from the Start
Seamlessly connecting discovery, preclinical, IND-enabling studies and commercial manufacturing reduces handoffs and accelerates data readiness for BLA/MAA.
2. Regulatory Focus and Intelligent Data Gathering
Using Target Product Profiles (TPP) and validated assays from day one ensures alignment with FDA/EMA expectations.
3. Scientific Execution by Design
A platform built on reproducibility, scalability and assay performance enables faster transitions across phases without resetting quality benchmarks.
A Real-World Framework for CGT Development
This presentation isn’t just theory. It offers a real-world framework from an experienced gene therapy CDMO—illustrating how structured feasibility, mirrored manufacturing systems and validated platforms can cut months off timelines.
The content will help you:
- Recognize where process variability can stall approvals
- Understand how platform validation supports speed and consistency
- Plan assay development aligned with late-stage requirements
References:
Watch the full video and learn how top programs are being guided through IND, BLA and MAA submissions with confidence.
Meet our Presenter
Additional Resources
Learn about our IND Enabling Packages
Explore our CGT Webinar Series
